bioMérieux
A global leader in in vitro diagnostics for clinical and industrial applications.
BIM | PA
Overview
Corporate Details
- ISIN(s):
- FR0013280286 (+13 more)
- LEI:
- 549300AK8Y0LBIQ4T071
- Country:
- France
- Address:
- 376 CHE DE L'ORME, 69280 MARCY-L'ETOILE
- Website:
- https://www.biomerieux.com/
- Sector:
- Manufacturing
Description
bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2021-12-10 07:01 |
bioMérieux – Relèvement des perspectives 2021
|
French | PDF • 166.9 KB | ||
| 2021-12-08 08:17 |
Novembre 2021 - Déclaration sur le nombre d'actions composant le capital social…
|
French | PDF • 16.0 KB | ||
| 2021-12-01 11:15 |
bioMérieux molecular tests efficiently detect SARS-CoV-2 Omicron variant
|
English | PDF • 34.2 KB | ||
| 2021-12-01 11:15 |
Les tests moléculaires bioMérieux détectent efficacement le variant Omicron du …
|
French | PDF • 253.2 KB | ||
| 2021-11-05 08:21 |
Octobre 2021 - Déclaration sur le nombre d'actions composant le capital social …
|
French | PDF • 205.5 KB | ||
| 2021-10-21 23:00 |
BAXTER ET BIOMÉRIEUX ANNONCENT LE MARQUAGE CE DU TEST NEPHROCLEAR™ CCL14 POUR P…
|
French | PDF • 259.8 KB | ||
| 2021-10-21 23:00 |
BAXTER AND BIOMÉRIEUX ANNOUNCE CE MARK FOR NEPHROCLEAR™ CCL14 TEST TO PREDICT P…
|
English | PDF • 189.7 KB | ||
| 2021-10-21 07:01 |
bioMérieux – Third-Quarter 2021 Business Review
|
English | PDF • 247.2 KB | ||
| 2021-10-21 07:01 |
bioMérieux – Information financière du 3ème trimestre 2021
|
French | PDF • 265.8 KB | ||
| 2021-10-08 08:52 |
Septembre 2021 - Déclaration sur le nombre d'actions composant le capital socia…
|
French | PDF • 205.5 KB | ||
| 2021-09-13 07:01 |
A survey in 5 European countries about sepsis demonstrates the lack of awarenes…
|
English | PDF • 69.2 KB | ||
| 2021-09-13 07:01 |
Une enquête au sujet du sepsis menée dans 5 pays européens démontre le manque d…
|
French | PDF • 458.3 KB | ||
| 2021-09-06 09:10 |
Août 2021 - Déclaration sur le nombre d'actions composant le capital social et …
|
French | PDF • 204.9 KB | ||
| 2021-09-02 17:36 |
Notice of publication of the 2021 half-year financial report
|
English | PDF • 195.4 KB | ||
| 2021-09-02 17:36 |
Avis de mise à disposition du rapport financier semestriel 2021
|
French | PDF • 195.5 KB |
Automate Your Workflow. Get a real-time feed of all bioMérieux filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for bioMérieux
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for bioMérieux via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-09-04 | N/A | Other | Sell | 1,432 | 137,517.82 EUR |
| 2023-09-04 | N/A | Other | Sell | 1,253 | 120,328.10 EUR |
| 2023-09-01 | N/A | Other | Other | 2,900 | N/A |
| 2023-06-23 | N/A | Other | Other | 323 | 24,971.13 EUR |
| 2023-06-23 | N/A | Other | Buy | 323 | 24,971.13 EUR |
| 2023-06-23 | N/A | Other | Buy | 300 | 23,193.00 EUR |
| 2023-06-23 | N/A | Other | Buy | 25 | 1,932.75 EUR |
| 2023-03-23 | N/A | Other | Sell | 16,500 | 1,650,415.80 EUR |
Peer Companies
